Selling Your Veterinary Practice to Mission Pet Health: A Vet’s 2026 Guide

Key takeaways

• Mission Pet Health is the post-merger combined entity of Southern Veterinary Partners (SVP) and Mission Veterinary Partners (MVP), formally launched in July 2025 per the Mission Pet Health press release at the time.
• Shore Capital Partners is a primary financial sponsor of the combined platform. The legacy SVP partnership-model acquisition playbook remains a centerpiece of Mission Pet Health’s deal approach.
• The Southeast and Sun Belt concentration is the geographic signature of the combined platform, reflecting the legacy SVP footprint with additional density from the MVP network.
• The partnership / co-ownership model is the structural through-line for Mission Pet Health offers. Sellers commonly retain 20 to 40 percent direct equity in the practice with negotiated put/call buyout mechanics.
• The most reliable way to know what Mission Pet Health — or any major buyer — would actually pay for your specific practice is to run a structured competitive process. We call ours the Elite Selling System: we hand-select and vet every buyer who gets to bid, the way a doorman with a velvet rope lets in only the right people, then run a private bidding window inside that vetted group. Mission Pet Health is invited inside that rope on practices that fit their criteria — and when they bid against a curated group of qualified competitors, the number is reliably very different from what they would offer in a direct, single-bidder conversation.

The shape of the Mission Pet Health conversation depends heavily on what the practice owner knew before the merger and what they know now. Practice owners who had been in active conversations with Southern Veterinary Partners through 2024 — sometimes for years — found those conversations continuing under a new banner from July 2025 onward, with much of the same deal team and the same partnership-model template.

Practice owners in the legacy MVP regions experienced the same shift from the other direction. And practice owners coming into the conversation for the first time now encounter Mission Pet Health as a single combined platform without necessarily knowing the merger context that shaped it.

The merger context matters because Mission Pet Health‘s distinguishing feature — the partnership-emphasis deal template — comes from one half of the combined platform (SVP) more than the other. The legacy SVP playbook centered partnership structures with retained practice-level equity as the standard transaction; the legacy MVP playbook leaned more conventional.

The combined platform appears to be standardizing around the SVP template per Mission Pet Health‘s external positioning, which means most current offers carry the partnership structure as the default.

What follows is the same picture I’d lay out over dinner if a vet handed me a Mission Pet Health offer and asked what to do with it. Who Mission Pet Health is, what the merger means for current and recently-engaged sellers, how the partnership model actually works, where the negotiation leverage sits in the post-merger context, and how to think about Mission Pet Health against the rest of the US veterinary buyer pool.

Quick facts on Mission Pet Health

Mission Pet Health is the post-merger combined entity formed by the consolidation of Southern Veterinary Partners (SVP) and Mission Veterinary Partners (MVP). The merger was formally announced and the combined platform launched in July 2025 per the Mission Pet Health press release at the time.

The combined platform is one of the largest US veterinary practice consolidators by hospital count.

Both legacy companies came from the same broader institutional category — PE-backed mid-market veterinary roll-ups — but with somewhat different geographic footprints and deal-structure emphases. Legacy Southern Veterinary Partners was concentrated in the Southeast (the company was founded in Birmingham, Alabama) and had built its reputation around partnership / co-ownership acquisition structures as the standard deal template.

Legacy Mission Veterinary Partners had a broader US footprint and used a mix of structures. The combined Mission Pet Health platform retains both geographic strengths, with particularly strong density across the Southeast and Sun Belt regions.

Shore Capital Partners is a primary financial sponsor of the combined platform per public ownership disclosures. Shore Capital is a Chicago-based private equity firm focused on the lower-middle-market healthcare services sector, with a long history in veterinary services dating back to the original SVP investment.

The exact post-merger ownership structure includes multiple investors per the Mission Pet Health press release.

The most important practical fact for a US seller. The partnership-model acquisition approach is the standard Mission Pet Health template. Sellers receiving outreach from Mission Pet Health — whether they previously interacted with SVP, MVP, or this is a first conversation — should expect partnership structures with retained practice-level equity to be the default deal format presented. That structural posture is one of the dimensions that most differentiates Mission Pet Health from the brand-handling-emphasis buyers (VCA) and the long-hold-strategic buyers (NVA, Mars).

What Mission Pet Health actually pays for veterinary practices in 2026

The consistent pattern we see on partnership-deal conversations. When a multi-doctor practice receives a direct partnership term sheet from any major partnership-model buyer — Mission Pet Health included — the structural terms reflect what the buyer perceives the seller will accept without competitive comparison. The headline cash percentage on the majority stake tends to be reasonable on its face; the structural dimensions that carry more long-term economic weight (the put formula multiple, the EBITDA base definition, the governance carve-outs, the integration protections, the interim liquidity rights) tend to be drafted toward the buyer side of the table in any first-draft document.

That is not unique to Mission Pet Health. It is the basic mechanics of how partnership-model templates get calibrated in the absence of competitive pressure.

Mission Pet Health does not publish a standard price sheet for any specific practice profile. Per industry M&A commentary (Octus, Capstone Partners, 2025-2026), competitive outcomes for strong multi-doctor general practices in the $2 million-plus revenue range tend to land in the low-teens EBITDA range across the major buyer pool.

The actual number for any specific practice depends heavily on whether other buyers are at the table and the specific profile of the practice. Mission Pet Health participates in this competitive band when they bid on qualifying practices, with the specific offer on any specific deal negotiated case by case under confidentiality.

For specialty hospitals, the broader market generally values these higher than comparable GP practices per industry research. Mission Pet Health‘s specialty footprint has grown through both legacy networks, and the combined platform may bid as a buyer for qualifying specialty platforms.

For larger multi-location groups ($10 million-plus revenue, $2 million-plus EBITDA), the multiple range typically extends higher than for single-location GP practices, with deal sizes scaling into the eight-figure-plus range. Mission Pet Health‘s combined-platform capital position from Shore Capital and other sponsors supports active bidding on larger platforms when the practice profile matches.

For practices in the Southeast and Sun Belt, Mission Pet Health‘s geographic density is particularly developed — the combined platform has more regional operational infrastructure in those markets than in less-saturated regions. That doesn’t translate directly to a higher headline number, but it can influence the operational synergies a Mission Pet Health bid is willing to underwrite, which feeds back into the negotiation.

The cash-at-close reality

For Mission Pet Health partnership offers, the headline cash-at-close figure on the majority stake is only one of three components determining the seller’s total economic outcome. The full math runs across: the wire that hits the bank on closing day for the majority stake, the present-value of the retained-equity buyout payment that lands when the put/call window opens (commonly year five in standard partnership structures), and any earnout component layered on the deal.

2025-2026 healthcare M&A commentary from Dechert LLP, Holland & Knight, and Capstone Partners shows the broader PE-backed pool concentrating the majority of nominal deal value in the cash-at-close component. For partnership structures specifically, the present-value of the retained-equity component — modeled honestly with realistic discount rates and protective formula provisions — frequently represents the largest single swing factor in total economic outcome between a well-negotiated and a poorly-negotiated partnership deal.

Two sentences worth memorizing before any Mission Pet Health partnership negotiation. The headline percentage Mission Pet Health acquires is less important than the formula multiple at the put window.

And the formula multiple at the put window is less important than the EBITDA-protection clauses that govern what counts in the EBITDA at the buyout date.

A note on deal structure types in the current market

The US veterinary M&A market has shifted measurably toward partnership and joint-venture structures over the past 18 months per MB Law Firm’s 2025 healthcare M&A commentary. Mission Pet Health (via the legacy SVP playbook), AmeriVet, Rarebreed Veterinary Partners, IVC Evidensia, and Encore Vet Group have publicly emphasized partnership variants in their company materials.

The trend reflects a broader institutional preference for keeping selling doctors economically aligned with practice-level performance during the post-close years.

Mission Pet Health‘s distinguishing position within this trend is that the platform inherited the longest-tenured partnership-model playbook in the US veterinary roll-up category. Legacy SVP had been refining the partnership template across years of acquisitions before the MVP merger, and the post-merger Mission Pet Health platform has continued that emphasis.

For sellers comparing partnership-template offers across the field, Mission Pet Health represents one of the more institutionally developed versions of the structure — though that institutional development cuts both ways in negotiation, since the platform’s standard template reflects accumulated negotiating experience that benefits the buyer side by default. Our PE pricing guide walks through the structure-by-structure comparison.

How Mission Pet Health’s acquisition team operates

Mission Pet Health‘s corporate-development team is staffed primarily by the legacy SVP deal team — the people who built the SVP partnership-model playbook over years of acquisitions — augmented with key MVP origination personnel post-merger. The team works the standard mix of channels: direct outreach to practice owners identified through industry data and broker relationships, participation in structured competitive sale processes run by qualified sell-side advisors, and inbound inquiries from owners reaching out independently.

A practical implication that’s specific to the post-merger period. Mission Pet Health is still consolidating the legacy SVP and MVP regional operating structures across the combined network.

For a seller engaging with the team in 2026, that means clarity on which legacy regional structure the new acquisition would join is one of the practical questions worth pressing in the conversation — the integration mechanics differ between the SVP regional structure and the MVP regional structure, and the seller’s post-close operational experience will reflect whichever regional structure inherits the new practice.

How Mission Pet Health integrates the practices it acquires

Mission Pet Health’s integration approach inherits the legacy SVP operational template — brand-preservation-emphasis with operational back-office consolidation — supplemented with the legacy MVP infrastructure across overlapping regions.

Local brand preservation. Per legacy SVP and Mission Pet Health company materials, the platform’s general approach is to preserve the practice name, signage, marketing materials, and customer-facing identity post-acquisition. The integration is focused on back-office and operational dimensions rather than customer-facing brand consolidation.

The specific brand handling for any acquired practice is determined under the definitive purchase agreement.

Shared back office. The platform provides centralized HR, accounting, payroll, vendor management, supply purchasing, marketing infrastructure, and IT support across the combined network. Integration timing in the post-merger period sometimes runs longer than the pre-merger legacy SVP cadence as the combined platform standardizes its operational infrastructure.

Partnership-equity governance. For acquired practices joining under a partnership structure, the governance provisions in the definitive purchase agreement define how the practice’s seller-retained equity interacts with the broader Mission Pet Health platform. Information rights, consent rights on material practice-level decisions, anti-dilution protections, and the put/call mechanics are all part of the governance package — and all deserve careful negotiation because the partnership template’s default settings reflect the platform’s accumulated experience, not the seller’s specific situation.

Continuing education and clinical programs. The combined platform brings together the continuing-education and clinical-development resources of both legacy networks. Specific programming and access details are determined under the platform’s integrated programming framework per Mission Pet Health company materials.

Doctor relationships. Per industry M&A commentary on PE-backed veterinary acquirers, selling owners commonly stay on as medical director or in a continuing clinical role for a multi-year post-close period. In partnership structures where the seller retains equity (the typical Mission Pet Health template), the post-sale role is typically tied to the partnership terms and the eventual put/call window.

Mission Pet Health’s recent activity in 2025-2026

Mission Pet Health is among the most active US veterinary practice acquirers in 2026, reflecting the combined-platform’s expanded capital position and origination pipeline. Capstone Partners‘ April 2026 Pet Sector M&A Update documents the broader sector acceleration entering Q1 2026, with the mid-market PE-backed segment that includes Mission Pet Health leading the rebound.

The post-merger period also brings specific operational considerations. Mission Pet Health is still completing the integration of legacy SVP and MVP regional operating structures, vendor contracts, and central services infrastructure.

For sellers in 2026, that means certain operational mechanics — vendor consolidation, central-services cost allocations, regional-management reporting — may shift between the time an offer is signed and the practical post-close experience plays out. The protective provisions in the definitive purchase agreement that govern these dimensions deserve sharper-than-usual attention in the post-merger window.

Have an offer from Mission Pet Health or SVP? Get a Free Practice Value Estimate — send us the offer and we’ll decompose the terms (including the partnership equity terms, if applicable), identify what’s typically negotiable, and project what your practice would likely clear in a structured competitive process with the broader qualified buyer pool. No upfront cost, no obligation.

How Mission Pet Health compares to the other major buyers

If you’re considering Mission Pet Health, you’re probably comparing them implicitly to the other major buyers who would compete for your practice. Here’s how Mission Pet Health stacks up.

Versus AmeriVet Veterinary Partners. Both AmeriVet and Mission Pet Health emphasize partnership / co-ownership structures as their distinguishing acquisition feature, which makes them direct competitors on the structural dimension. AmeriVet is dual-sponsor (AEA Investors + Oaktree Capital) while Mission Pet Health is primarily Shore-sponsored.

The choice between them often comes down to specific deal-term differences (put formula multiples, EBITDA-protection clauses, governance carve-outs) and regional fit. Our AmeriVet buyer profile covers the partnership-model dimensions in depth.

Versus VetCor (Harvest Partners). VetCor is one of the longest-tenured PE-backed veterinary platforms in the United States, with a refined integration playbook spanning more than two decades. VetCor’s default structure leans more traditional (100-percent acquisition with rollover equity) than Mission Pet Health‘s partnership-default approach.

The choice typically comes down to whether the seller prefers a partnership structure with retained practice-level equity (Mission Pet Health) or a more traditional rollover into a more institutionally tenured platform (VetCor). Our VetCor buyer profile covers VetCor’s institutional-depth dimensions.

Versus NVA (JAB Holdings). NVA is a long-hold strategic, distinguishable from PE-fund-cycle platforms. NVA’s deal structures are determined case by case, while Mission Pet Health’s partnership-default makes its structural template more predictable.

Both preserve local practice branding per their respective company materials. Our NVA buyer profile covers the NVA-specific dimensions.

Versus Mars Veterinary Health (VCA, BluePearl, Banfield). Mars is the strategic family-owned exception in the buyer pool, structurally distinct from Mission Pet Health‘s PE-backed partnership-default approach. Brand-handling philosophy also differs — Mars (via VCA) has historically consolidated practices under a Mars-network brand while Mission Pet Health preserves local identity.

For sellers prioritizing brand preservation, that distinction is meaningful. Our Mars Veterinary Health buyer profile covers the Mars-specific dimensions.

Versus PetVet Care Centers (Ares Management). PetVet operates a meaningful US footprint per PetVet company materials. Both Mission Pet Health and PetVet may compete for qualifying practices in a structured sale process, with deal terms determined case by case.

The structural-default difference (Mission Pet Health partnership vs. PetVet more conventional) often drives the seller’s choice between them.

Versus the smaller PE-backed groups (Thrive Pet Healthcare, Alliance Animal Health, Heartland, VPP, Rarebreed, others). Each has its own integration philosophy and target profile. Rarebreed specifically also emphasizes partnership structures, putting it in direct competition with Mission Pet Health on the structural dimension.

Smaller groups sometimes pay more aggressively for practices that fill specific geographic or specialty gaps. The right way to evaluate which buyer pays most is to put all of them in a competitive process and let them surface their best offers in parallel.

What to negotiate before signing with Mission Pet Health

Seven priorities when negotiating with Mission Pet Health’s acquisition team, with the partnership-structure mechanics and the post-merger-integration provisions as the highest-leverage categories.

Partnership-equity put/call mechanics (highest priority if applicable). If the Mission Pet Health offer is structured as a partnership (the standard template), the most consequential terms are the put formula multiple, the EBITDA base definition at the buyout date, the protective EBITDA-allocation clauses (limits on platform cost allocations to the practice), the governance carve-outs (information rights, consent rights, anti-dilution), and the platform-exit alignment. Each of these moves only under competitive pressure.

Post-merger integration protections. Mission Pet Health is still integrating legacy SVP and MVP operations. Negotiate explicit language on: which legacy regional operating structure your practice joins, the timing and approach for any vendor-contract transitions, the central-services cost-allocation methodology that will apply during the earnout window, and the operational-decision-rights framework.

Each of these can affect practice-level EBITDA during the partnership hold period.

Cash at close percentage on the majority stake. Push for higher cash percentages on the percentage Mission Pet Health is acquiring. Every dollar shifted from contingent to cash is guaranteed money instead of conditional.

Brand preservation in writing. Mission Pet Health‘s stated approach is local brand preservation, but “general approach” language in marketing materials is not the same as contractual commitment. Negotiate explicit brand-preservation language in the definitive purchase agreement — practice name, signage, website, marketing materials.

Non-compete scope. Non-competes commonly run several years and cover a defined geographic radius for all veterinary work. Negotiate: shorter duration (1 to 2 years), tighter radius (5 to 10 miles), or carve out specific specialty or modality if you might continue clinical work post-employment.

Post-sale clinical autonomy. Medical director arrangements are standard in partnership structures, but the protective terms matter: clinical autonomy (you make medicine decisions, not the regional team), staffing autonomy (you keep the team you’ve trained), and a clear definition of which business decisions stay with you versus migrating to the Mission Pet Health regional operating structure.

Platform-exit alignment. Shore Capital and the other sponsors will eventually exit Mission Pet Health through a sale or recapitalization event. The seller’s partnership-equity outcome depends on how the put/call mechanics align with that future exit.

If the put right is exercisable before the platform exit, the formula price applies; if the put is structured to participate in the platform exit, the seller’s outcome is tied to the platform-level valuation at that future date. Either approach can work, but the alignment needs to be explicit.

The post-merger context, in depth

For sellers evaluating Mission Pet Health specifically, the most useful frame is to think clearly about the practical implications of the SVP+MVP merger across the next few years of operational integration.

What the merger inherited. The combined platform brought together the SVP partnership-deal playbook (refined over years of acquisitions in the Southeast/Sun Belt) and the MVP operational infrastructure (built across a broader US footprint). The result is a larger combined platform with two parallel legacy operating models that are being merged across 2025-2026 and beyond.

What this means in 2026 specifically. The integration is mid-flight. Vendor contracts are being consolidated.

Central-services infrastructure is being unified. Regional operating structures are being rationalized.

These integrations affect practice-level operational mechanics, which in turn affect practice-level EBITDA during the post-close years. For a seller entering a partnership structure in this window, the protective provisions that limit how these integrations can affect the practice’s EBITDA at the put-window calculation are particularly important.

What this means after the integration completes. Once Mission Pet Health‘s combined platform is fully integrated, the operational mechanics will stabilize. The platform’s scale and Sun Belt density will be assets for sellers whose practices fit the geographic concentration.

For sellers entering the partnership now, the timing question is whether the integration window creates short-term risk that’s outweighed by the platform’s combined scale and operational depth over the longer hold period.

The honest answer depends on the specific practice and the specific partnership terms. Sellers who go into the conversation with strong protective provisions and a competitive process behind them tend to land outcomes where the platform’s scale works for them; sellers who sign the standard direct template carry more of the integration-window risk.

Should I take a Mission Pet Health offer or run a competitive process?

For Mission Pet Health partnership offers, the competitive process matters more than it does for straight 100-percent acquisitions. The reason is structural: a 100-percent acquisition has one big number to negotiate, while a partnership has six or eight structural terms that each carry significant long-term economic weight.

Put formula multiple. EBITDA base definition.

Protective EBITDA-allocation clauses. Governance carve-outs.

Interim liquidity rights. Platform-exit alignment.

Each of these moves only under competitive pressure.

A properly run competitive process puts the entire partnership term sheet on the table for negotiation simultaneously. Other partnership-model bidders — AmeriVet, Rarebreed Veterinary Partners, regional specialty groups offering co-ownership variants — return their own term sheets, and the seller’s lawyers can read every clause against every other clause in parallel.

Mission Pet Health then either matches the best terms seen across the field or loses on a dimension they don’t have to lose on. Either outcome is better for the seller.

What our Elite Selling System actually does

For a Mission Pet Health partnership transaction, our process is structured around the recognition that the cash multiple is unlikely to be the dimension where the deal lands well or poorly — the partnership-structure mechanics are.

Step one — the partnership-template audit. We deconstruct the Mission Pet Health partnership template clause by clause and compare it against the comparable templates we’ve seen from the rest of the partnership-emphasis buyer pool (AmeriVet, Rarebreed, the broader field). Where does the Mission Pet Health put formula sit against competitors’ formulas?

What EBITDA-protection clauses are in their draft, and which standard ones are missing? Where do the governance carve-outs differ from the protective minimums we’ve seen in well-negotiated partnership exits?

Step two — the curated bidder mix. From the 42-plus veterinary consolidators TE actively tracks, we invite only the ones whose profile genuinely competes with Mission Pet Health on this specific practice — geographic density (Sun Belt/Southeast overlap matters here), partnership-structure capability, deal size band, integration philosophy. The bidder mix typically includes three or four partnership-model competitors alongside two or three 100-percent buyers, so the seller can compare structural variants directly.

Step three — the term-by-term comparison. Bidders return their full term sheets. The seller sees side-by-side comparisons across every structural dimension.

The seller’s economic outcome under each scenario is modeled with present-value discounting and downside-case stress tests on the partnership mechanics. The seller chooses on the dimensions that matter to her — sometimes the highest cash percentage, sometimes the cleanest put formula, sometimes the strongest brand-preservation language.

The economic result holds across partnership deals: practices in the qualifying revenue band that run our process consistently clear materially better total economic outcomes — typically multiple seven figures, sometimes more — than the same practice would have cleared by signing the direct Mission Pet Health term sheet without exploring the field.

Closing thought

Mission Pet Health enters 2026 as one of the largest US veterinary consolidators, with a partnership-emphasis acquisition playbook inherited from the legacy SVP deal team and a combined-platform scale that supports active bidding across the Southeast, Sun Belt, and broader US markets. For sellers who fit the partnership structure — willing to retain practice-level equity and stay economically aligned with the platform’s performance during the hold period — the Mission Pet Health template represents one of the most institutionally developed versions of the structure available in the market.

What separates a well-negotiated Mission Pet Health partnership outcome from a mediocre one isn’t the cash-at-close number. It’s the structural mechanics of the retained equity: the put formula multiple, the EBITDA-protection clauses, the governance carve-outs, the post-merger-integration provisions that limit how SVP+MVP consolidation can affect practice-level EBITDA at the put-window calculation.

Those terms determine whether the partnership produces materially higher total economic value than a straight 100-percent sale or whether it produces a slow leak across the hold period.

If a Mission Pet Health partnership term sheet is on your desk right now — or if you’re in early conversations with the team after years of SVP outreach — the highest-leverage move is to understand how the field would structure the same practice on different partnership terms before signing anything that pre-commits the structural mechanics. Get a Free Practice Value Estimate and we’ll lay out the same structural comparison we would for a client across a dinner table.

Sources

Industry M&A research and valuation data

1. Capstone Partners. Pet Sector M&A Update — April 2026. Capstone Partners industry research.
2. Octus. Veterinary Services Roll-Up Coverage, 2025-2026. Octus credit research and industry commentary.
3. Dechert LLP. Healthcare M&A: 2025-2026 Trends and Outlook. Dechert healthcare practice publications.
4. Holland & Knight. Healthcare Private Equity 2025-2026 Commentary. Holland & Knight healthcare practice publications.
5. MB Law Firm. 2025 Healthcare M&A Trends — Joint Venture and Partnership Structures. MB Law Firm healthcare publications.

Mission Pet Health, legacy SVP/MVP, and parent company materials

6. Mission Pet Health press release, July 21, 2025 — Announcement of SVP+MVP merger and combined platform launch.
7. Mission Pet Health. About Mission Pet Health and combined US footprint. Mission Pet Health company materials, 2025-2026.
8. Southern Veterinary Partners. Legacy SVP partnership-model materials. SVP company materials archived 2024-2025.
9. Shore Capital Partners. Portfolio and healthcare services investment practice. Shore Capital company materials.

Veterinary practice operations, benchmarks, and profession data

10. iVET360. State of the Veterinary Industry — 2026 Industry Report. iVET360 industry research.
11. American Veterinary Medical Association (AVMA). 2026 AVMA Veterinary Economic Report. AVMA economic research.